This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cabotegravir oral

Updated 2 Feb 2023 | Other antiretrovirals


Oral formulation of cabotegravir.

Drugs List

  • cabotegravir 30mg tablets
  • VOCABRIA 30mg tablets
  • Therapeutic Indications


    HIV infection in adults- in combination with other antiretrovirals

    Short-term treatment, in combination with rilpivirine tablets, of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

    Oral lead in to assess tolerability of cabotegravir and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.

    Oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.


    Cabotegravir tablets are indicated for the short-term treatment of HIV in combination with rilpivirine tablets, therefore the prescribing information for rilpivirine tablets should be consulted for recommended dosing.

    Healthcare professionals should carefully select patients who agree to the required monthly injection schedule and counsel patients about the importance of adherence to scheduled dosing visits to help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance with missed doses.


    Oral lead in
    Cabotegravir tablets with rilpivirine tablets should be taken for approximately one month (at least 28 days) prior to initiation of cabotegravir injection to assess tolerability.
    One cabotegravir tablet should be taken with one rilpivirine 25mg tablet, once daily.

    Oral dosing for missed injections of cabotegravir
    If a patient plans to miss a scheduled injection visit by more than 7 days, oral therapy may be used to replace up to 2 consecutive monthly injection visits or one, every 2 month injection visit. For oral therapy durations greater than two months, an alternative oral regimen is recommended.
    The first dose of oral therapy should be taken one month (+/- 7 days) after the last injection doses of cabotegravir and rilpivirine for patients been given monthly injections.
    For patients being given every 2 month injections, the first dose of oral therapy should be taken 2 months (+/- 7 days) after the last injection.
    Injection dosing should be resumed on the day oral dosing completes.

    Additional Dosage Information

    Missed doses
    Patient should take the missed dose as soon as possible, providing the next dose is not due within 12 hours. If the next dose is due within 12 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
    If a patient vomits within 4 hours of taking cabotegravir tablets, another cabotegravir tablet should be taken.


    Children under 18 years
    Hepatitis B

    Precautions and Warnings

    Obese patients with a BMI equal or greater than 30kg/m2
    Patients over 65 years
    End stage renal disease
    Glucose-galactose malabsorption syndrome
    Hepatitis C
    HIV infection with A6 or A1 subtype
    Lactose intolerance
    Severe hepatic impairment

    Treatment does not prevent risk of transmission of HIV
    Advise ability to drive/operate machinery may be affected by side effects
    HIV therapy: Must be used in combination with other antiretrovirals
    Treatment should be initiated by doctor experienced in HIV management
    Contains lactose
    Autoimmune disorders can occur many months after initiation of treatment
    Monitor hepatic enzymes
    Discontinue immediately following signs of acute hepatotoxicity
    Inflammatory symptoms should be evaluated and treated appropriately
    May develop immune reactivation syndrome
    Risk of developing opportunistic infections
    Discontinue if hypersensitivity reactions occur
    Take another dose if vomiting occurs within 4 hours

    Cabotegravir has not been studied in patients with end-stage renal disease on renal replacement therapy. Since cabotegravir is greater than 99% protein bound, dialysis is not expected to modify exposures of cabotegravir. If administration is required to a patient on renal replacement therapy, cabotegravir should be used with caution.

    Prior to starting treatment, it should be taken into account that multivariable analyses indicated that a combination of at least 2 of the following baseline factors may be associated with an increased risk of virological failure: archived rilpivirine resistance mutations, HIV-1 subtype A6/A1, or BMI equal or greater than 30kg/metres squared.

    Limited data is available in patients with hepatitis C co-infection. Monitoring of liver function is recommended in patients with hepatitis C co-infection.

    Typically, immune reactivation syndrome reactions have been observed within the first few weeks or months of initiation of the antiretroviral treatment. For example, cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia. Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been observed, however, the reported time to onset is more variable and these reactions can occur many months after initiation of treatment.

    Pregnancy and Lactation


    Cabotegravir is contraindicated during pregnancy.

    The manufacturer advises that cabotegravir tablets are not recommended during pregnancy unless the expected benefit justifies the potential risk to the foetus. There is a limited amount of data from the use of cabotegravir in pregnancy, the effect on human pregnancy is unknown. Cabotegravir was not teratogenic when studied in pregnant rats and rabbits but, exposures higher than the therapeutic dose showed reproductive toxicity in animals.


    Cabotegravir is contraindicated during breastfeeding.

    The manufacturer recommends that HIV infected women do not breastfeed their infants under any circumstances in order to avoid transmission of HIV. It is expected that cabotegravir will be excreted into human breast milk based on animal data, although this has not been confirmed in humans.

    Side Effects

    Abdominal pain
    Autoimmune disorders
    Autoimmune hepatitis
    Dream abnormalities
    Graves' disease
    Hypersensitivity reactions
    Increase in serum transaminases
    Opportunistic infections
    Serum bilirubin increased
    Weight gain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Vocabria 30mg film-coated tablets. ViiV Healthcare UK Limited. Revised June 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.